Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
Randomised data will be needed to answer lingering questions about DKN-01.